Kala falls on mixed data for dry eye candidate

By Chris Lieu | Jan 6, 2018 | 12:19 AM GMT

Kala Pharmaceuticals Inc. (NASDAQ:KALA) lost $5.08 (29%) to $12.26 on Friday after reporting mixed data from the Phase III STRIDE 1 and STRIDE 2 trials of KPI-121